RxDoctor Payments Data

Li Cai, MD

Internal Medicine · Houston, TXNPI 1902860612

Payments from drug & device makers

$9,538in general payments, 2019–2025

Across 449 payments — averaging $21.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Biohaven Pharmaceuticals, Inc.$1K
  • Boehringer Ingelheim$958
  • Amgen$660
  • GSK$456
  • Bayer$440
  • plus $4K from 35 others

What the payments were for

  • Consulting fees$1,20013%
  • Travel & lodging$731%
  • Food & beverage$8,23786%
  • Education$280%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,538 in reported general payments places this provider in the 90th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$273,804
Medicare patients
434
Services billed
5,137

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide53$71,830
JardianceEmpagliflozin62$63,013
EliquisApixaban55$45,539
NuplazidPimavanserin Tartrate17$41,918
MyrbetriqMirabegron29$30,339
RybelsusSemaglutide11$27,219
SynjardyEmpagliflozin/Metformin Hcl16$26,332
MounjaroTirzepatide19$21,937
TrulicityDulaglutide18$20,280
FarxigaDapagliflozin Propanediol13$20,167
Synjardy XrEmpagliflozin/Metformin Hcl13$19,590
VascepaIcosapent Ethyl14$14,562
XareltoRivaroxaban13$13,681
JanuviaSitagliptin Phosphate17$5,520
Levothyroxine Sodium519$5,423

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy, Synjardy Xr$958$108,93491 claims
Novo NordiskOzempic, Rybelsus$1,438$99,04964 claims
PfizerEliquis$228$45,53955 claims
Lilly USA, LLCMounjaro, Trulicity$344$42,21637 claims
Astellas Pharma US IncMyrbetriq$209$30,33929 claims
AstraZenecaFarxiga$331$20,16713 claims
Johnson & JohnsonXarelto$312$13,68113 claims
MerckJanuvia$212$5,52017 claims
AbbVieSynthroid$64$3,34646 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →